Differential modulation of immune recognition molecules by iuterleukin-7 in human acute leukaemias

European Cytokine Network

Volumn 10, Issue 1, 1999, Pages 87-95

  Costello, Régis T ^a   Mallet, Françoise ^a   Chambost, Hervé ^a,b   Sainty, Danielle ^a   Gastaut, Jean Albert ^a   Olive, Daniel ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b TIMONE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Adhesion molecules; Costimulatory molecules; Immunotherapy; Interleukin 7

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 7; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; LYMPHOCYTE PROLIFERATION; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CYTOKINES; GENES, MHC CLASS I; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-D ANTIGENS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-7; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, T-CELL, ACUTE; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

ANIMALIA;

EID: 0032946323     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Costello R, Imbert J, Olive D. 1993. Interleukin-7, a major T lymphocyte cytokine. (Review) Eur. Cytokine Netw. 4: 253.
2. Armitage R J, Namen A E, Sassenfeld H M, Grabstein KH. 1990. Regulation of human T cell proliferation by IL-7. J. Immunol. 144: 938.
3. Londei M, Verhoef A, Hawrylowicz C, Groves J, de Berardinis P, Feldmann M. 1990. Interleukin-7 is a growth factor for mature human T cells. Eur. J. Immunol. 20: 425.
4. Costello R, Brailly H, Mallet F, Mawas C, Olive D. 1993. Interleukin-7 is a potent co-stimulus of the adhesion pathway involving CD2 and CD28 molecules. Immunology 80: 451.
5. Costello R, Mawas C, Olive D. 1993. Differential immunosuppressive effects of metabolic inhibitors on T lymphocyte activation. Eur. Cytokine Netw. 4: 139.
6. Jicha D L, Mule J J, Rosenberg S A. 1991. Interleukin-7 generates anti-tumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J. Exp. Med. 174: 1511.
7. Alderson M R, Sassenfeld H M, Widmer MB. 1990. Interleukin-7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp. Med. 172: 577.
8. Smyth M J, Norihisa Y, Gerard J R, Young H A, Ortaldo J R. 1991. IL-7 regulation of cytotoxic lymphocytes: pore-forming protein gene expression, interferon-gamma production, and cytotoxicity of human peripheral blood lymphocytes subsets. Cell Immunol. 138: 390.
9. + NK cells. J. Immunol. 148: 2429.
10. + natural killer cells. A comparative study. J. Immunol. 147: 2208.
11. Alderson M R, Tough T W, Ziegler S F, Grabstei K H. 1991. Interleukin-7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J. Exp. Med. 173: 923.
12. Damia G, Komschlies KL, Faltynek C R, Ruscetti F W, Wiltrout R H. 1992. Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice. Blood 79: 1121.
13. Morrissey P J, Conlon P, Braddy S, Williams D E, Namen A E, Mochizuki D Y. 1991. Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J. Immunol. 146: 1547.
14. Lynch D H, Namen A E, Miller R E. 1991. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21: 2977.
15. Mavroudis D, Barrett J. 1996. The graft-versus-leukemia effect. (Review) Curr. Opin. Hematol. 3: 423.
16. Goldman J M, Gale R P, Horowitz M M, Biggs J C, Champlin R E, Gluckman E, Hoffmann R G, Jacobsen S J, Marmont A M, McGlave P B. 1988. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T cell depletion. Ann. Intern. Med. 108: 806.
17. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. 1995. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 345: 1144.
18. Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A G, Gralnick H, Sultan C. 1985. Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 103: 626.
19. + T cells. Eur. J. Immunol. 23: 608.
20. SPSS User's Guide. SPSS Inc ed. SPSS Inc; 1993.
21. Townsend S E, Su F W, Atherton J M, Allison J P. 1994. Specificity and longevity of anti-tumor immune responses induced by B7-transfected tumors. Cancer Res. 54: 6477.
22. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. 1997. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood 90: 4901.
23. Costello R T, Mallet F, Sainty D, Maraninchi D, Gastaut J A, Olive D. 1998. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur. J. Immunol 28: 90.
24. Cardoso A A, Schultze J L, Boussiotis V A, Freeman G J, Seamon M J, Laszlo S, Billet A, Sallan S E, Gribben J G, Nadler L M. 1996. Pre-B acute lymphoblastic leukemia cells may induce T cell anergy to alloantigen. Blood 88: 41.
25. Schirren C A, Volpel H, Meuer S C. 1992. Adhesion molecules on freshly recovered T leukemias promote tumor-directed lympholysis. Blood 79: 138.
26. Olive D, Lopez M, Blaise D, Viens P, Stoppa A M, Brandely M, Mawas C, Mannnoni P, Maraninchi D. 1991. Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2. J. Immunother. 10: 412.
27. Olive D, Chambost H, Sainty D, Stoppa A M, Blaise D, el Marsafy S, Brandely M, Mannoni P, Mawas C, Maraninchi D. 1994. Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2. Leukemia 8: 1230.
28. Oblakowski P, Bello Fernandez C, Reittie J E, Heslop H E, Galatowicz G, Veys P, Wilkes S, Prentice H G, Haslehurst G, Hoffbrand A V, Brenner M K. 1991. Possible mechanism of selective killing of myeloid leukemic blast cells by LAK cells. Blood 77: 1996.
29. Cerdan C, Costello R, Collette Y, Mawas C, Olive D. 1998. Co-stimulation of T cell immune response: a potential role in tumor immunology. In: Chouaib S, ed. Research in...: The biotherapy of cancers, from immunotherapy to gene therapy, Paris: INSERM, 151.
30. June C H, Bluestone J A, Nadler L M, Thompson C B. 1994. The B7 and CD28 receptor families. (Review) Immunol. Today 15: 321.
31. Schultze J, Nadler L M, Gribben J G. 1996. B7-mediated costimulation and the immune response. (Review) Blood Rev. 10: 111.
32. Guinan E C, Gribben J G, Boussiotis V A, Freeman G J, Nadler L M. 1994. Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. (Review) Blood 84: 3261.
33. Engel P, Tedder T F. 1994. New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens. (Review) Leuk. Lymphoma 13 (suppl 1): 61.
34. Freeman G J, Gribben J G, Boussiotis V A, Ng J W, Restivo V A Jr, Lombard L A, Gray G S, Nadler L M. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see comments]. Science 262: 909.
35. Engel P, Gribben J G, Freeman G J, Zhou L J, Nozawa Y, Abe M, Nadler L M, Wakasa H, Tedder T F. 1994. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 84: 1402.
36. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier L L, Banchereau J. 1994. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180: 1841.
37. Matulonis U A, Dosiou C, Lamont C, Freeman G J, Mauch P, Nadler L M, Griffin J D. 1995. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85: 2507.
38. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler L M, Griffin J D. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated anti-leukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156: 1126.
39. Dunussi-Joannopoulos K, Weinstein H J, Nickerson P W, Strom T B, Burakoff S J, Croop J M, Arceci R J. 1996. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87: 2938.
40. Delabie J, Ceuppens J L, Vandenberghe P, de Boer M, Coorevits L, de Wolf-Peeters C. 1993. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 82: 2845.
41. Munro J M, Freedman A S, Aster J C, Gribben J G, Lee N C, Rhynhart K K, Banchereau J, Nadler L M. 1994. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 83: 793.
42. Delabie J, Chan W C, Weisenburger D D, de Wolf-Peeters C. 1995. The antigen-presenting cell function of Reed-Sternberg cells. (Review) Leuk. Lymphoma 18: 35.
43. Van den Hove L E, van Goll S W, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts M A, Ceuppens J L. 1997. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 11: 572.
44. Schultze J L, Cardoso A A, Freeman G J, Seamon M J, Daley J, Pinkus G S, Gribben J G, Nadler L M. 1995. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 92: 8200.
45. Freeman G J, Freedman A S, Segil J M, Lee G, Whitman J F, Nadler L M. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143: 2714.
46. Shamash J, Davies D C, Salam A, Rohatiner A Z, Young B D, Lister T A. 1995. Induction of CD80 expression in low-grade B cell lymphoma - a potential immunotherapeutic target. Leukemia 9: 1349.
47. Eder M, Ottmann O G, Hansen-Hagge T E, Bartram C R, Falk S, Gillis S, HoelzerD, Ganser A. 1992. In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells. Blood 79: 3274.
48. Touw I P, Pouwels K, van Agthoven A J, van Gurp R, Delwel R, Hagemeijer A, Hahlen K, Lowenberg B. 1990. Role of interleukin-7 in the growth of acute lymphoblastic leukemia. Bone Marrow Transplant. 6 (suppl. 1): 36.
49. Eder M, Ottmann O G, Hansen-Hagge T E, Bartram C R, Gillis S, Hoelzer D, Ganser A. 1990. Effects of recombinant human IL-7 on blast cell proliferation in acute lymphoblastic leukemia. Leukemia 4: 533.
50. + acute lymphoblastic leukemia cell line, OM9; 22. Leukemia 7: 1034.